CONCISE REPORT

Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study

Annie Yarwood,1 Sebastien Viatte,1 Yukinori Okada,2,3,4,5,6 Robert Plenge,7 Kazuhiro Yamamoto,8,9 BRAGGSS, RACI, Anne Barton,1,10 Deborah Symmons,10,11 Soumya Raychaudhuri,1,12 Lars Klareskog,13 Peter Gregersen,14 Jane Worthington,1,10 Steve Eyre17

Handling editor Tore K Kvien

Objectives A recent study identified 16 genetic variants associated with N-glycosylation of human IgG. Several of the genomic regions where these single nucleotide polymorphisms (SNPs) reside have also been associated with autoimmune disease (AID) susceptibility, suggesting there may be pleiotropy (genetic sharing) between loci controlling both N-glycosylation and AIDs. We investigated this by testing variants associated with levels of IgG N-glycosylation for association with rheumatoid arthritis (RA) susceptibility using a Mendelian randomisation study, and testing a subset of these variants in a less well-powered study of treatment response and severity.

Methods SNPs showing association with IgG N-glycosylation were analysed for association with RA susceptibility in 14 361 RA cases and 43 923 controls. Five SNPs were tested for association with response to anti-tumour necrosis factor (TNF) therapy in 1081 RA patient samples and for association with radiological disease severity in 342 patients.

Results Only one SNP (rs9296009) associated with N-glycosylation showed an association (p=6.92×10^{-266}) with RA susceptibility, although this was due to linkage disequilibrium with causal human leukocyte antigen (HLA) variants. Four regions of the genome harboured SNPs associated with both traits (shared loci); although statistical analysis indicated that the associations observed for the two traits are independent. No SNPs showed association with response to anti-TNF therapy. One SNP rs12342831 was modestly associated with Larsen score (p=0.05).

Conclusions In a large, well-powered cohort of RA patients, we show SNPs driving levels of N-glycosylation have no association with RA susceptibility, indicating colocalisation of associated SNPs are not necessarily indicative of a shared genetic background or a role for glycosylation in disease susceptibility.

INTRODUCTION

Glycosylation, a post-translational protein modification in which a carbohydrate is attached to a hydroxyl group, was first implicated in rheumatoid arthritis (RA) when serum IgG glycosylation was associated with the disease. IgG antibodies have one conserved N-glycosylation site in the Fc portion of their heavy chains, shown to influence the structure and effector functions of IgG antibodies where distinct patterns of glycosylation on anticitrullinated protein antibodies have been detected prior to the onset of RA. In addition, a lack of total IgG Fc galactosylation has been shown to correlate with RA disease activity and severity, with levels of N-terminal glycosylation being restored by treatment with anti-tumour necrosis factor (TNF) drugs. Therefore, there is accumulating evidence and interest in the hypothesis that glycosylation plays a role in susceptibility and outcome in RA.

A recent genome-wide association analysis identified 10 confirmed loci (p<2.27×10^{-8}) and 7 strongly suggestive loci (p<5×10^{-8}) associated with N-glycosylation of human IgG. Several of the loci identified have previously been associated with autoimmune diseases (AIDs); therefore, it has been suggested that there may be pleiotropy (shared genetic contribution) between loci controlling N-glycosylation and loci controlling AIDs.

To investigate this theory, we have performed a Mendelian randomisation study, testing variants previously associated with levels of IgG N-glycosylation for association with RA susceptibility. We also tested a subset of these single nucleotide polymorphisms (SNPs) in a smaller cohort for any indication that they may be involved in treatment response or severity in RA. Association of the same variants that control IgG N-glycosylation with susceptibility to or outcome of RA would provide an unbiased confirmation of the hypothesis that N-glycosylation is important in RA.

METHODOLOGY

Susceptibility analysis

The samples and data analysis, described previously, were from 18 studies with a total of 14 361 RA cases and 43 923 controls of European ancestry. This provided 98% power to detect an OR=1.10 at the 0.05 significance level (α), for a SNP with minor allele frequency (MAF)=20%. SNPs showing evidence of association with IgG N-glycosylation were analysed for association with RA (table 1). Of the 17 SNPs, 16 were selected for analysis, while no data were available for 1 SNP (rs1049110) in the human leukocyte antigen (HLA) region. Association analysis consisted of logistic regression correcting for up to 10 principal
Table 1 Meta-analysis results, testing SNPs associated with glycosylation for association with RA

<table>
<thead>
<tr>
<th>Chr</th>
<th>SNP position</th>
<th>Locus</th>
<th>Allele 1</th>
<th>Allele 2</th>
<th>Number of studies in meta-analysis</th>
<th>Number of cases</th>
<th>Number of controls</th>
<th>Frequency of allele 1</th>
<th>Beta coefficient</th>
<th>SE</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Rs11710456</td>
<td>186725887 ST6GAL1</td>
<td>A</td>
<td>G</td>
<td>11</td>
<td>8875</td>
<td>29 367</td>
<td>0.28</td>
<td>0.017</td>
<td>0.02</td>
<td>0.44</td>
</tr>
<tr>
<td>3</td>
<td>Rs7652995</td>
<td>186722944 ST6GAL1</td>
<td>A</td>
<td>G</td>
<td>11</td>
<td>8875</td>
<td>29 367</td>
<td>0.84</td>
<td>−0.006</td>
<td>0.03</td>
<td>0.84</td>
</tr>
<tr>
<td>5</td>
<td>Rs17348299</td>
<td>55322895 IL6ST-ANKRD55</td>
<td>A</td>
<td>C</td>
<td>11</td>
<td>8875</td>
<td>29 367</td>
<td>0.16</td>
<td>−0.028</td>
<td>0.02</td>
<td>0.29</td>
</tr>
<tr>
<td>7</td>
<td>Rs6421315</td>
<td>50355207 1KZFL</td>
<td>G</td>
<td>C</td>
<td>18</td>
<td>14 361</td>
<td>43 923</td>
<td>0.61</td>
<td>0.05</td>
<td>0.01</td>
<td>0.003</td>
</tr>
<tr>
<td>7</td>
<td>Rs1122979</td>
<td>15091507 ABCF2-SMARCD3</td>
<td>A</td>
<td>G</td>
<td>11</td>
<td>8875</td>
<td>29 367</td>
<td>0.12</td>
<td>−0.04</td>
<td>0.035</td>
<td>0.20</td>
</tr>
<tr>
<td>7</td>
<td>Rs12342831</td>
<td>33124872 84GALT1</td>
<td>T</td>
<td>C</td>
<td>17</td>
<td>13 964</td>
<td>43 524</td>
<td>0.74</td>
<td>−0.03</td>
<td>0.02</td>
<td>0.07</td>
</tr>
<tr>
<td>11</td>
<td>Rs4930561</td>
<td>67931761 5UV420H1</td>
<td>A</td>
<td>G</td>
<td>11</td>
<td>8875</td>
<td>29 367</td>
<td>0.49</td>
<td>0.04</td>
<td>0.02</td>
<td>0.03</td>
</tr>
<tr>
<td>14</td>
<td>Rs11847263</td>
<td>65775695 FUT8</td>
<td>T</td>
<td>G</td>
<td>11</td>
<td>8875</td>
<td>29 367</td>
<td>0.66</td>
<td>−0.006</td>
<td>0.02</td>
<td>0.77</td>
</tr>
<tr>
<td>22</td>
<td>Rs2186369</td>
<td>24170996 SMARCB1-DEL3</td>
<td>T</td>
<td>G</td>
<td>11</td>
<td>8875</td>
<td>29 367</td>
<td>0.84</td>
<td>0.04</td>
<td>0.03</td>
<td>0.18</td>
</tr>
<tr>
<td>22</td>
<td>Rs909674</td>
<td>39859169 SYNGR1-TAB1-MGAT3-CACNA1</td>
<td>A</td>
<td>C</td>
<td>18</td>
<td>14 361</td>
<td>43 923</td>
<td>0.73</td>
<td>−0.02</td>
<td>0.02</td>
<td>0.23</td>
</tr>
<tr>
<td>6</td>
<td>Rs9296009</td>
<td>32114515 PRR1</td>
<td>T</td>
<td>A</td>
<td>18</td>
<td>14 361</td>
<td>43 923</td>
<td>0.79</td>
<td>−0.61</td>
<td>0.02</td>
<td>6.92×10^-266</td>
</tr>
<tr>
<td>6</td>
<td>Rs1049110</td>
<td>32726803 HLA-DQA2, HLA-DQB2</td>
<td>SNP not in data</td>
<td>SNP not in data</td>
<td>18</td>
<td>14 361</td>
<td>43 923</td>
<td>0.42</td>
<td>0.003</td>
<td>0.02</td>
<td>0.85</td>
</tr>
<tr>
<td>7</td>
<td>Rs404256</td>
<td>90657783 6ACH2</td>
<td>T</td>
<td>C</td>
<td>18</td>
<td>14 361</td>
<td>43 923</td>
<td>0.42</td>
<td>0.003</td>
<td>0.02</td>
<td>0.85</td>
</tr>
<tr>
<td>7</td>
<td>Rs2072209</td>
<td>107392198 LAMB1</td>
<td>A</td>
<td>G</td>
<td>17</td>
<td>12 841</td>
<td>33 416</td>
<td>0.93</td>
<td>0.03</td>
<td>0.03</td>
<td>0.35</td>
</tr>
<tr>
<td>9</td>
<td>Rs4878639</td>
<td>36093999 RECK</td>
<td>T</td>
<td>C</td>
<td>11</td>
<td>8875</td>
<td>29 367</td>
<td>0.72</td>
<td>−0.002</td>
<td>0.02</td>
<td>0.93</td>
</tr>
<tr>
<td>12</td>
<td>Rs12828421</td>
<td>7335217 PEX5</td>
<td>T</td>
<td>C</td>
<td>10</td>
<td>7355</td>
<td>18 860</td>
<td>0.48</td>
<td>0.004</td>
<td>0.02</td>
<td>0.84</td>
</tr>
<tr>
<td>17</td>
<td>Rs7224668</td>
<td>7923788  SLC38A10</td>
<td>T</td>
<td>C</td>
<td>11</td>
<td>8875</td>
<td>29 367</td>
<td>0.45</td>
<td>−0.02</td>
<td>0.02</td>
<td>0.24</td>
</tr>
</tbody>
</table>

Loci shown in bold italics have previously been associated with RA (different SNP). The LD between the glycosylation SNP and RA SNP in these regions are shown in table 2. SNP p values in the individual studies included in the meta-analysis can be found in online supplementary table S1.

Chr, chromosome; LD, linkage disequilibrium; RA, rheumatoid arthritis.
components. A genome-wide association study meta-analysis was then performed using an inverse variance method assuming a fixed effects model on the effect estimates ($\beta$).

**Treatment response analysis**

Genotype data were available for five of the SNPs associated with glycosylation in 1039 RA patient samples from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS). Multivariate linear regression was carried out to test the association of each SNP with response to anti-TNF treatment, measured as either absolute change in DAS28 from baseline to 6 months, or according to the 6-month response criteria defined by European League Against Rheumatism (EULAR). All regression analyses were adjusted for covariates known to be predictors of response in this cohort; baseline DAS28, baseline Health Assessment Questionnaire score, concurrent disease-modifying anti-rheumatic drug therapy and gender, as described previously. As patients in the cohort received different anti-TNF drugs, a stratified analysis was also carried out.

**Outcome/severity analysis**

Lack of total IgG Fc galactosylation has been shown to correlate with RA disease activity and severity. Data were available for five SNPs in patient samples from the Norfolk Arthritis Register, a primary care-based inception cohort of patients with recent onset inflammatory polyarthritis. These were tested for association with disease severity defined as radiographic damage measured by Larsen score and erosions. A generalised linear regression model was used to analyse SNP associations with erosions as a binary variable, using generalised estimating equations (STATAs xtgee). The analysis incorporated time points up to 5 years of follow-up for all patients, and was performed for disease duration <7.5 years. Generalised linear latent and mixed modelling was used to test the association of SNPs associated with glycosylation for association with Larsen score. To account for change in the tested variable (eg, Larsen score) over time, disease duration was included in all models, along with the linear quadratic terms of disease duration to account for nonlinear changes over time. The same was done for age at onset as described previously. We also found no evidence association with any of the five glycosylation SNPs tested with treatment response measured by change in DAS28 or EULAR response (see online supplementary tables S1 and S2). Stratified analysis showed a modest association between rs9296009 in the PRRT1 locus (p=0.02) and response to etanercept (n=346) measured by change in DAS28, but not when response was measured by EULAR criteria. A modest association was also seen with a SNP in the HLA-DRB1 region (rs9268839) and response to infliximab when measured by change in DAS28 (p=0.035) (n=322) and EULAR response criteria (p=0.002) (n=330) (see online supplementary tables S1 and S2).

One SNP, rs12342831, was modestly associated with severity in patients meeting American College of Rheumatology (ACR) criteria cumulatively after 5 years (n=221) (p=0.054) (see online supplementary table S3).

**RESULTS**

Of the 16 SNPs previously associated with glycosylation only one SNP (rs9296009) showed association with RA (p=6.92×10$^{-55}$); however, this SNP lies within the HLA region which confers the largest genetic association with RA. The glycosylation SNP is in modest linkage disequilibrium (LD) with the most associated variants in this region (rs660895/rs6910071 (both tag HLA-DRB1*0401) r$^2=0.29$, D$^2=0.55$) and the effect observed at the glycosylation SNP is not independent of the HLA-DRB1 susceptibility SNPs.

The HLA association with RA can be almost completely explained by five amino acid positions, three in HLA-B and HLA-DPB1. Conditioning on these five amino acids showed no evidence of a residual association in the region. Therefore, the glycosylation SNP, rs9296009, is not the lead, causal SNP in the region and there is no evidence it is independently associated with RA susceptibility.

One other SNP (rs6421315), within the IKZF1 gene, showed modest association with RA (p=0.003). For four non-HLA loci, which contain both a SNP associated with glycosylation and a SNP associated with RA susceptibility, we examined the extent to which these associations are likely to arise from a shared genetic signal by assessing the extent of LD between the glycosylation associated SNPs and the RA associated SNPs (table 2). No evidence of significant LD was found between the SNPs in an independent dataset of 4861 European samples with genotypes available at >55 000 SNPs, suggesting that the associations observed for the two traits at these loci are independent. Further, no evidence of association was detected to the 340 SNPs from the 17 loci that showed evidence of association to a range of glycosylation traits.

**DISCUSSION**

In a large, well-powered cohort of RA patients, a Mendelian randomisation approach showed no evidence to support the hypothesis that SNPs associated with N-glycosylation of IgG are associated with susceptibility to RA.

One SNP in the IKZF1 locus showed modest association with RA in the meta-analysis (p=0.003), although it did not remain significant after correcting for multiple testing for 16 SNPs (Bonferroni corrected p value 0.05). Interestingly, IKZF1 knock-out mice were shown to have different expression of IgG

<table>
<thead>
<tr>
<th>Chr</th>
<th>SNPs associated with glycosylation (9)</th>
<th>Locus</th>
<th>SNP associated with RA (reference)</th>
<th>r2</th>
<th>D$^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>rs17348299</td>
<td>IL6ST-ANKRD55</td>
<td>rs7162411</td>
<td>0.003</td>
<td>0.214</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>rs7731626</td>
<td>0.002</td>
<td>0.149</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rs6859219</td>
<td>0.001</td>
<td>0.167</td>
</tr>
<tr>
<td>9</td>
<td>rs12342831</td>
<td>B4GALT1</td>
<td>rs11574914 (RA locus named CCL19-CCL21)</td>
<td>0</td>
<td>0.011</td>
</tr>
<tr>
<td>22</td>
<td>rs909674</td>
<td>SYNGR1-TAB1-MGAT3-CACNA1</td>
<td>rs909685 (RA locus named SYNGR1)</td>
<td>0.108</td>
<td>0.848</td>
</tr>
<tr>
<td>6</td>
<td>rs404256</td>
<td>BACH2</td>
<td>rs72928036</td>
<td>0</td>
<td>0.023</td>
</tr>
</tbody>
</table>

Linkage disequilibrium was calculated in an independent dataset of 4861 European samples where data was available for >55 000 SNPs. Chr, chromosome; RA, rheumatoid arthritis.
N-glycans when compared with wild type. Further, different IgG N-glycan profiles exist in patients with systemic lupus erythematosus (SLE) when compared with controls, making this locus an intriguing target for further investigation. Although this locus shows no evidence for association with RA, it is associated with SLE and other AID including type 1 diabetes (T1D). However, there is only very low LD between the locus and the T1D variants respectively (rs2366293 r2 = 0.04 D’ = 0.6, rs10272724 r2 = 0.001, D’ = 0.032) suggesting possible independence. A previous study of 127 female RA patients, followed for 6 years, showed that patients with a higher percentage of agalactosyl IgG oligosaccharides G(O) in serum had significantly more erosions and disease activity than patients with lower levels. Therefore, we tested the association of glycosylation SNPs with both response to anti-TNF therapy and disease severity in RA patients but found no evidence to support the theory that glycosylation SNPs predict outcome. Although larger than the previous study, it should be noted that the severity analysis remained underpowered, and is a major limitation of the analysis. Hence, results should be interpreted with caution and it is recommended that investigation of the effect of these glycosylation SNPs on disease outcome should be repeated in a larger cohort.

Information on glycosylation was not available in our cohort, and therefore, we could not directly test the association of variants with glycosylation. However, the use of Mendelian randomisation in the largest sample size to date has demonstrated that SNPs associated with glycosylation are not the same as those associated with RA as previously suggested, highlighting that care should be taken when inferring causality. This does not mean that glycosylation is not involved in RA; it could be a biomarker of RA as it has been shown to appear several years before disease onset.

Author affiliations

1Faculty of Medical and Human Sciences, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
2Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
3Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
4Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA
5Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
6Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
7Merck Research Laboratories, Merck & Co. Inc., Boston, Massachusetts, USA
8Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
9Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
10NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
11Faculty of Medical and Human Sciences, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, Stopford Building, The University of Manchester, Manchester, UK
12Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
13Rheumatology Unit, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden
14The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, New York, USA

Correction notice The license of this article has changed since publication to CC BY 4.0.

Acknowledgements The authors would like to thank Arthritis Research UK for their support (grant ref R116361). They acknowledge support from the National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit and from the innovative medicines initiative joint undertaking (IMI JU) funded project BeTheCure, (contract no. 115142-2). They also thank RACI, BRAGGSS and NOAR for the use of samples and data.

Collaborators BRAGGSS RACI.


Funding Arthritis Research UK (20385).

Competing interests None declared.

Ethics approval The study was approved by the North West West Central ethics committee COREC 04/Q1403/37, and the North West Ethics Committee (MREC 99/8/B4).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.

REFERENCES